Bispecific Or Bifunctional, Or Multispecific Or Multifunctional, Antibody Or Fragment Thereof Patents (Class 424/136.1)
  • Patent number: 10323099
    Abstract: Multispecific antibodies based on antibodies that share a common light chain are described herein. The multispecific antibodies include: modified heavy chains having, by domain exchange, a common light chain variable domain VL; and two modified light chains having, by domain exchange, variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of such antibodies and their use.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: June 18, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Wolfgang Schaefer
  • Patent number: 10287352
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 14, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • Patent number: 10266608
    Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 23, 2019
    Assignee: EpimAb Biotherapeutics, Inc.
    Inventor: Chengbin Wu
  • Patent number: 10191034
    Abstract: A method for assessing the risk of potential adverse effects for a human patient receiving a CD19×CD3 bispecific antibody is provided. The method comprises determining the total B count in the patient, and identifying a B cell number indicative of a patient at risk of potential adverse effects from the antibody. The method further provides a dosing schedule for administering the antibody to the patient identified as at risk of potential adverse effects. Also provided is a pharmaceutical package or kit comprising a first dose and a second dose, and optionally a third dose, of the CD19×CD3 bispecific antibody as defined in the methods/dosage regimen of the disclosure.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: January 29, 2019
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventor: Dirk Nagorsen
  • Patent number: 10188729
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • Patent number: 10168339
    Abstract: It is an object of the present invention to provide a marker substance capable of accurately determining a risk of developing metabolic syndrome in vivo. That is, the present invention provides the followings: a marker peptide for determining the risk of developing the metabolic syndrome; an antibody or an aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome; a microarray in which the antibody or the aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome has been immobilized on a carrier; a method for determining the risk of developing the metabolic syndrome, comprising measuring an amount or the presence or absence of the marker peptide for determining the risk of developing the metabolic syndrome in a biological sample collected from a subject; and a kit for determining the risk of developing the metabolic syndrome, comprising the antibody or the aptamer or comprising the microarray.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: January 1, 2019
    Assignee: LION CORPORATION
    Inventors: Chiyoko Uchiyama, Kei Kurita, Eriko Fukushima, Riichi Maki
  • Patent number: 10081679
    Abstract: The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: September 25, 2018
    Assignee: CCAM BIOTHERAPEUTICS LTD.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Edna Meilin
  • Patent number: 10077315
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: September 18, 2018
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Patent number: 10072081
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: September 11, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Bellur S. Prabhakar, Chenthamarakshan Vasu, Palash Bhattacharya
  • Patent number: 10072098
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: September 11, 2018
    Assignee: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Patent number: 10047163
    Abstract: Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: August 14, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventor: David Liu
  • Patent number: 10000569
    Abstract: An anti-EGFR/anti-HER3 antibody or antigen binding fragment thereof, and a method of preventing and/or treating a cancer using the same.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: June 19, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Kwang Ho Cheong, Jae Woong Hwang, Seung Hyun Lee, Powei Lin, Mi Young Cho
  • Patent number: 9988611
    Abstract: The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (VEGF) pathway and methods for using these fusion proteins.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 5, 2018
    Assignees: AP Biosciences, Inc., Innovent Biologics, Inc.
    Inventors: Jeng-Horng Her, Huang-Tsu Chen
  • Patent number: 9970849
    Abstract: An improved method for the preparation of target specific surfaces and uses thereof is described. In particular, the surfaces are bound to mono-specific tetrameric antibody complexes prior to their addition to a sample containing target entities and separating them from non-target entities.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: May 15, 2018
    Assignee: StemCell Technologies Inc.
    Inventor: Andy Isamu Kokaji
  • Patent number: 9958461
    Abstract: The present invention relates to methods and kits for detecting the interaction between a first membrane protein and a second protein in mammalian cells as well as to identify molecules that can disrupt protein to protein interactions. The invention relies on the functional reconstitution of an active human ubiquitin by two inactive fragments upon the interaction of two proteins attached through a linker to the inactive fragments. The reconstituted ubiquitin is then cleaved by human ubiquitin proteases resulting in the release of an artificial transcription factor, which in turn activates a reporter gene transcription. Activation of the reporter gene is indicative of the interaction between the two proteins.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: May 1, 2018
    Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Igor Stagljar, Julia Petschnigg, Bella Groisman
  • Patent number: 9951118
    Abstract: The HIV-specific cytotoxic T lymphocyte (CTL) response is a critical component in controlling HIV replication and is an important part of the ultimate failure to eradicate the virus. Disclosed herein are methods for genetically enhancing the HIV-specific CTL response to allow long-term viral suppression or viral clearance. Human hematopoietic stem cells (HSCs) were genetically modified such that they differentiate into mature CTLs that will kill HIV infected cells. As disclosed herein, the functional effector cells are not human leukocyte antigen (HLA)-restricted. As disclosed herein, stem cells are transduced with non-HLA restricted chimeric antigen receptors (CARs) that allow the recognition of HIV or HIV-infected cells when expressed by a CTL. These CARs are hybrid molecules that contain an extracellular HIV recognition domain and an intracellular TCR-zeta signaling domain. The CTL response may be enhanced through the targeting of T cell inhibitory receptors.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: April 24, 2018
    Assignee: The Regents of the University of California
    Inventors: Scott G. Kitchen, Jerome A. Zack, Otto O. Yang, Irvin Chen, Masakazu Kamata
  • Patent number: 9944709
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: April 17, 2018
    Assignee: CELLECTIS
    Inventor: Roman Galetto
  • Patent number: 9915665
    Abstract: System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: March 13, 2018
    Assignee: ABBVIE INC.
    Inventors: Lorenzo Benatuil, Jennifer Perez, Chung-Ming Hsieh
  • Patent number: 9914776
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: March 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Patent number: 9896513
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
  • Patent number: 9884117
    Abstract: Stable formulations are provided that contain immunoglobulin single variable domains at a high concentration. The formulations are useful as pharmaceutical formulation and suitable for subcutaneous administration. The formulations can be transported and stored under various stress conditions. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: February 6, 2018
    Assignee: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Marc Jozef Lauwereys
  • Patent number: 9885711
    Abstract: The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: February 6, 2018
    Assignee: XOMA Technology Ltd.
    Inventors: Mark L. White, Marina Roell, John Corbin, Robert Bauer, Daniel Bedinger
  • Patent number: 9884921
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 6, 2018
    Assignee: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • Patent number: 9856319
    Abstract: Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: January 2, 2018
    Assignee: ABBVIE INC.
    Inventors: Tariq Ghayur, Jijie Gu
  • Patent number: 9828434
    Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: November 28, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jianhua Sui
  • Patent number: 9783611
    Abstract: The invention relates to specific anti-HER3 antibodies, that bind to the beta-hairpin of HER3, their preparation and use as medicament.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 10, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Birgit Bossenmaier, Richard Buick, Michael Gerg, Frank Kroner, Gerhard Niederfellner, Carmen Peess, Michael Schraeml
  • Patent number: 9783609
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: October 10, 2017
    Assignees: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Patent number: 9782410
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: October 10, 2017
    Assignee: REXAHN PHARMACEUTICALS, INC.
    Inventors: Young B. Lee, Deog J. Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
  • Patent number: 9765157
    Abstract: The present invention provides a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds a human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: September 19, 2017
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, Peter Kufer, Patrick Hoffmann, Tobias Raum, Ralf Lutterbüse, Elisabeth Nahrwold, Claudia Blumel
  • Patent number: 9758805
    Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: September 12, 2017
    Assignee: Merus N.V.
    Inventors: Cornelis Adriaan De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
  • Patent number: 9745381
    Abstract: Certain embodiments are directed to a bispecific immunoglobulin that is capable of binding cell surface molecules on a target cell, such as cancer cells, and cell surface molecules on immune effector cell, such as cytotoxic T lymphocytes, resulting in the targeted killing of target cells. In certain aspects a Bif is a polypeptide comprising a first target binding domain that specifically binds a cancer cell, a second effector binding domain that specifically binds an immunologic effector, and an immunoglobulin constant region linker operatively coupling the first and second binding domain.
    Type: Grant
    Filed: May 18, 2013
    Date of Patent: August 29, 2017
    Assignee: Scott & White Healthcare (SWH)
    Inventors: Jen-Sing Liu, Shu-Ru Kuo
  • Patent number: 9738728
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: August 22, 2017
    Assignee: Sanofi
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Patent number: 9732162
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 15, 2017
    Assignee: Sanofi
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Patent number: 9725520
    Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 8, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ningyan Zhang, Zhiqiang An
  • Patent number: 9718893
    Abstract: The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: August 1, 2017
    Assignee: SYNIMMUNE GMBH
    Inventors: Gundram Jung, Michael Durben, Ludger Grosse-Hovest
  • Patent number: 9688763
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: June 27, 2017
    Assignee: Novartis AG
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Patent number: 9657107
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: May 23, 2017
    Assignee: GENMAB A/S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Patent number: 9637541
    Abstract: An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: May 2, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyung-Chan Kim, Kyung Eun Kim, Yoon Sook Lee, Mi Young Cho
  • Patent number: 9624291
    Abstract: An antibody is provided. The antibody comprises an Fc region and a Fab region, wherein: (i) the Fc region comprises two non-identical heavy chains, wherein at least one of the two non-identical heavy chains comprises an amino acid modification so as to form complementation between the two non-identical heavy chains thereby increasing the probability of forming heterodimers of the non-identical heavy chains and decreasing the probability of forming homodimers of identical heavy chains; and (ii) the Fab region comprises a first covalent link between a first heavy chain and a first light chain of the Fab region and a second covalent link between a second heavy chain and a second light chain of said Fab region, wherein a position of the first covalent link relative to the first heavy chain is different to a position of the second covalent link relative to the second heavy chain.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: April 18, 2017
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Itai Benhar, Lilach Vaks
  • Patent number: 9623117
    Abstract: The present invention provides methods and reagents for directing the selective targeting and entry of bacterial toxins to mammalian cells. Methods include the step of contacting a cell with a bacterial toxin or toxic bioactive fragment thereof associated with an antibody or ligand that is specific to a target on the cell, wherein the antibody or ligand selectively binds the target on the cell and the bacterial toxin or fragment thereof is internalized and enters the cell. The invention further encompasses compositions and kits to carry out the methods.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: April 18, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Edwin Raymond Chapman, Felix Leejia Yeh
  • Patent number: 9611325
    Abstract: The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against a surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against a surface antigen HER2 of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: April 4, 2017
    Assignee: Wuhan YZY Biopharma Co., Ltd.
    Inventors: Pengfei Zhou, Jing Zhang, Lingli Hu, Rui Wang, Xiang Zhou, Kesu Fan
  • Patent number: 9605242
    Abstract: The invention relates to a method performed ex vivo for removal of tumor cells from intraoperatively collected blood salvage, to antibodies and scaffold proteins which mimic antibodies for use in said ex vivo method, to the use of said ex vivo method for removal of tumor cells from intraoperatively collected blood salvage followed by reintroducing the so obtained purified blood salvage or of concentrates of erythrocytes purified by said method to a patient from whom said intra-operatively collected blood was obtained, as well as to blood salvage or a concentrate of erythrocytes, both obtainable by said method for reinfusion to said patient.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: March 28, 2017
    Assignee: Horst Lindhofer
    Inventors: Horst Lindhofer, Michael Stroehlein, Markus Heiss
  • Patent number: 9605076
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: March 28, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Patent number: 9587022
    Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: March 7, 2017
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Ruijiang Song, David D. Ho
  • Patent number: 9587012
    Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 7, 2017
    Assignee: AARON DIAMOND AIDS RESEARCH CENTER
    Inventors: David D. Ho, Yaoxing Huang, Jian Yu
  • Patent number: 9580509
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: February 28, 2017
    Assignee: MedImmune, LLC
    Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
  • Patent number: 9562092
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: February 7, 2017
    Assignee: True North Therapeutics, Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 9527920
    Abstract: The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: December 27, 2016
    Assignee: CENTRO DE IMMUNOLOGIA MOLECULAR
    Inventors: Ernesto Moreno Frias, Gertrudis Rojas Dorantes, Ana Victoria Casadesus Pazos
  • Patent number: 9522956
    Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: December 20, 2016
    Assignee: L'Institut National de la Sante et de la Recherche Medicale
    Inventors: Stephen D. Gillies, David Azria, Christel Larbouret, André Pelegrin
  • Patent number: 9470683
    Abstract: A method of determining aggregates of a macromolecule monomer in a fluid containing the macromolecule, comprises the steps of: contacting a sample of the fluid with a sensing surface of an interaction analysis sensor, wherein the sensing surface is capable of specific binding interaction with the macromolecule, determining at least one kinetic parameter for the interaction of the fluid sample with the sensing surface, comparing the determined kinetic parameter or parameters with that or those determined for at least one fluid sample having a known fraction or fractions of aggregates of the macromolecule, and determining therefrom the fraction of macromolecule in the sample that is in the form of aggregate or aggregates.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: October 18, 2016
    Assignee: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Stefan Lofas, Bjorn Persson